https://www.sciedu.ca/journal/index.php/jhm/issue/feedJournal of Hematological Malignancies2018-06-09T19:17:45-07:00Daniel Leejhm@sciedupress.comOpen Journal Systems<img style="float: right; padding: 10px;" title="http://www.sciedu.ca/journal/public/site/images/jhm/homepageimage_en_us_407" src="/journal/public/site/images/jhm/homepageimage_en_us_407.jpg" alt="http://www.sciedu.ca/journal/public/site/images/jhm/homepageimage_en_us_407" width="312" height="407" /><p><strong>>> The journal is under re-structure, and will not accept new submissions. Thanks. </strong></p><p><span style="font-size: 10px;">Journal of Hematological Malignancies (ISSN 1925-4024, EISSN 1925-4032) is an open access international scientific journal providing a forum for peer-reviewed articles, reviews or commentary related to all aspects of the prevention, diagnosis and management of malignancies of the blood system, as well as related molecular and cell biology, genetics, pathophysiology, epidemiology, and randomized controlled trials and evidence-based meta-analysis or pooled analysis related to specific trials.</span></p><p>JHM is included in:</p><ul><li>EBSCOhost</li><li>Gale's Academic Databases</li><li>Google Scholar</li><li>Lockss</li><li>PKP Open Archives Harvester</li><li>ProQuest</li><li>The Standard Periodical Directory</li></ul><p><span style="font-size: 10px;">To facilitate rapid publication and minimize administrative costs, JHM accepts <span>submissions </span><a href="/journal/index.php/jhm/about/submissions">online</a><span> or by e-mail (<a href="mailto:%6a%68%6d@%73%63%69%65%64%75%70%72%65%73%73.%63%6f%6d">jhm@sciedupress.com</a></span><span>).</span></span><span style="font-size: 10px;"> For online submission, please register and then follow the instructions given.</span></p><p>JHM’s Section:<br />Original Research, Case Report, Conference Report, Reviews.</p><p>---------------------------------------------------------------------</p><p> </p>https://www.sciedu.ca/journal/index.php/jhm/article/view/13151Acute Monocytic Leukemia Linked to Pulmonary Infiltrates and the Importance of Early Induction Chemotherapy2018-06-09T19:17:45-07:00Yvonne Chuyvonnelchu@gmail.comUmit Tapanyvonnelchu@gmail.comAdam Lerneryvonnelchu@gmail.com<p>Currently there is no consensus on the approach to evaluating lung infiltrates in patients with newly diagnosed acute myeloid leukemia (AML), a rare disease with an incidence of 3-4 cases per 100,000 people. The CT findings of pulmonary infiltrates in patients with AML are nonspecific and can range from confluent air-space opacities with patchy consolidation to interstitial markings and multiple subpleural small nodules. Biopsy will most often reveal bacterial or fungal infection and rarely malignant infiltrates. Here is a case of a patient with newly diagnosed AML, specifically of the monoblastic subtype, who was admitted to the hospital for induction chemotherapy and underwent transthoracic lung biopsy that confirmed monoblastic leukemic infiltrates. Following chemotherapy there was complete resolution of the lung infiltrates.</p>2018-06-09T01:09:43-07:00Copyright (c) 2018 Journal of Hematological Malignancies